Document is current
Any future updates will be listed below
-
Authors
Martins-Silva, Thais https://orcid.org/0000-0001-5049-2435
dos Santos Vaz, Juliana https://orcid.org/0000-0002-2880-767X
Schäfer, Julia Luiza https://orcid.org/0000-0002-5882-6775
Salum, Giovanni Abrahão https://orcid.org/0000-0002-7537-7289
Carpena, Marina Xavier https://orcid.org/0000-0002-4690-5791
Vitola, Eduardo Schneider https://orcid.org/0000-0002-6053-1132
Breda, Vitor https://orcid.org/0000-0002-1349-5220
Grevet, Eugênio Horacio https://orcid.org/0000-0002-6898-7126
de Mola, Christian Loret https://orcid.org/0000-0002-5264-5914
Barros, Fernando https://orcid.org/0000-0001-5973-1746
Menezes, Ana Maria Baptista
Gonçalves, Helen https://orcid.org/0000-0001-6470-3352
Wehrmeister, Fernando C. https://orcid.org/0000-0001-7137-1747
Rohde, Luis Augusto https://orcid.org/0000-0002-4552-4188
Tovo-Rodrigues, Luciana https://orcid.org/0000-0002-8732-6059
- License Information
-
More Information
Article History
Received: 6 July 2021
Revised: 31 October 2021
Accepted: 9 February 2022
First Online: 2 March 2022
Competing interests
: LAR has received grant or research support from, served as a consultant to, and served on the speakers’ bureau of Aché, Bial, Medice, Novartis/Sandoz, Pfizer/Upjohn, and Shire/Takeda in the last 3 years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by LAR have received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Novartis/Sandoz and Shire/Takeda. LAR has received authorship royalties from Oxford Press and ArtMed. All other authors declare that they have no conflicts of interest.
